Biovaxys Technology Corp (BIOV)

Currency in CAD
0.022
+0.003(+12.50%)
Delayed Data·
BIOV Scorecard
Full Analysis
Stock has taken a big hit over the last week
Trading near 52-week Low
Fair Value
Day's Range
0.0200.022
52 wk Range
0.0200.080
Key Statistics
Bid/Ask
0.055 / 0.07
Prev. Close
0.065
Open
0.02
Day's Range
0.02-0.022
52 wk Range
0.02-0.08
Volume
21K
Average Volume (3m)
241.09K
1-Year Change
-59.09%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIOV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Biovaxys Technology Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Biovaxys Technology Corp Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, a formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy. In addition, the company develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health’s proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. Further, the company operates HapTenix Platform, a vaccine platform based on the established immunological concept that modifies surface proteins with haptens and T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies triggered by exposure to peanut/tree nuts or eggs. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.

Compare BIOV to Peers and Sector

Metrics to compare
BIOV
Peers
Sector
Relationship
P/E Ratio
−1.0x−0.9x−0.5x
PEG Ratio
−0.030.010.00
Price/Book
−2.4x0.8x2.6x
Price / LTM Sales
-0.7x3.3x
Upside (Analyst Target)
-101.1%43.5%
Fair Value Upside
Unlock10.1%6.3%Unlock

Earnings

Latest Release
Jun 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

BIOV Income Statement

FAQ

What Stock Exchange Does Biovaxys Technology Trade On?

Biovaxys Technology is listed and trades on the Canadian Securities Exchange stock exchange.

What Is the Stock Symbol for Biovaxys Technology?

The stock symbol for Biovaxys Technology is "BIOV."

What Is the Biovaxys Technology Market Cap?

As of today, Biovaxys Technology market cap is 6.60M.

What Is Biovaxys Technology's Earnings Per Share (TTM)?

The Biovaxys Technology EPS (TTM) is -0.02.

From a Technical Analysis Perspective, Is BIOV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Biovaxys Technology Stock Split?

Biovaxys Technology has split 1 times.

How Many Employees Does Biovaxys Technology Have?

Biovaxys Technology has 0 employees.

What is the current trading status of Biovaxys Technology (BIOV)?

As of 05 Aug 2025, Biovaxys Technology (BIOV) is trading at a price of 0.02, with a previous close of 0.07. The stock has fluctuated within a day range of 0.02 to 0.02, while its 52-week range spans from 0.02 to 0.08.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.